Showing results (61-70 of 107) with videos related to

Sort By:
Pageof 11
American Journal of Obstetrics and Gynecology|February 18, 2014
A chemoresponse assay for prediction of platinum resistance in primary ovarian cancerThomas C Krivak, Shashikant Lele, Scott Richard, et al.
Plos One|November 8, 2012
Associations between gene expression variations and ovarian cancer risk alleles identified from genome wide association studiesHua Zhao, Jie Shen, Dan Wang, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 20, 2008
Prostate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinomaPaulette Mhawech-Fauceglia, Dominic J Smiraglia, Wiam Bshara, et al.
Gynecologic Oncology|July 12, 2005
A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancerSameer Sharma, Feng Qian, Bernadette Keitz, et al.
Plos One|June 19, 2009
Complex segregation analysis of pedigrees from the Gilda Radner Familial Ovarian Cancer Registry reveals evidence for mendelian dominant inheritanceBamidele O Tayo, Richard A DiCioccio, Yulan Liang, et al.
Gynecologic Oncology|August 21, 2009
Treatment of early-stage uterine papillary serous carcinoma at Roswell Park Cancer Institute, 1992-2006Nana E Tchabo, Susan McCloskey, Terry L Mashtare, et al.
The New England Journal of Medicine|January 6, 2006
Intraperitoneal cisplatin and paclitaxel in ovarian cancerDeborah K Armstrong, Brian Bundy, Lari Wenzel, et al.
Scientific Reports|November 16, 2017
A dual-channel endoscope for quantitative imaging, monitoring, and triggering of doxorubicin release from liposomes in living miceJeremy Kress, Daniel J Rohrbach, Kevin A Carter, et al.
Cancer Immunity|October 19, 2004
SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancerJonathan Tammela, Achim A Jungbluth, Feng Qian, et al.
JAMA Oncology|November 19, 2020
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical TrialEmese Zsiros, Sarah Lynam, Kristopher M Attwood, et al.
Pageof 11